A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
Public ClinicalTrials.gov record NCT06112756. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause. Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life. The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances. The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo. For this, the researchers will analyze * change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment * change in the total number of minutes a participant wakes up at night after going to sleep after 12 weeks of treatment compared to before treatment * change in the participant's total time asleep while in bed after 4 and 12 weeks of treatment compared to before treatment. The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks. Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned. During the study, the doctors and their study team will: * take blood and urine samples * do physical examinations * check vital signs * do sleep tests * use an electronic hand-held device to record sleep quality and hot flashes at home An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Study identification
- NCT ID
- NCT06112756
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 65 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2023
- Primary completion
- Aug 21, 2024
- Completion
- Nov 6, 2024
- Last update posted
- Nov 9, 2025
2023 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Preferred Research Partners | Little Port Walter | Alaska | 72211 | — |
| MomDoc Women's Health Research | Scottsdale, AZ | Scottsdale | Arizona | 85251 | — |
| Diagnamics | Encinitas, CA | Encinitas | California | 92024 | — |
| SDS Clinical Trials Inc | Santa Ana | California | 92705 | — |
| Pacific Clinical Research Management Group LLC | Upland | California | 91786 | — |
| Helix Biomedics LLC | Boynton Beach, FL | Boynton Beach | Florida | 33435 | — |
| Sweet Hope Research Specialty, Inc. - Hialeah | Hialeah | Florida | 33016 | — |
| PharmaDev Clinical Research Institute, LLC | Miami | Florida | 33176 | — |
| Segal Trials - Women's Health & General Medicine Research Site | North Miami | Florida | 33161 | — |
| Palm Beach Research center | West Palm Beach | Florida | 33409 | — |
| Sleep Practitioners, LLC | Macon | Georgia | 31210 | — |
| SleepCare Research Institute Inc | Stockbridge | Georgia | 30281 | — |
| Brengle Family Medicine | Indianapolis | Indiana | 46260 | — |
| Revive Research Institute, Inc. - Women's Health | Dearborn Heights | Michigan | 48127 | — |
| Essential Women's Health Associates | Las Vegas | Nevada | 89113 | — |
| Clinilabs Drug Development Corporation-Feasibility | Eatontown | New Jersey | 07724 | — |
| CTI Clinical Research Center | Cincinnati | Ohio | 45212 | — |
| Intrepid Research, LLC. | Cincinnati | Ohio | 45245 | — |
| Bogan Sleep Consultants, LLC | Columbia | South Carolina | 29201 | — |
| FutureSearch Trials of Neurology LP | Austin | Texas | 78731 | — |
| Sleep Therapy and Research Center | Medical Center Drive Office | San Antonio | Texas | 78229 | — |
| Road Runner Research, Ltd. | San Antonio | Texas | 78249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06112756, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2025 · Synced Sep 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06112756 live on ClinicalTrials.gov.